X4 PHARMACEUTICALS, INC Increase (Decrease) in Inventories
X4 PHARMACEUTICALS, INC (XFOR) reported Increase (Decrease) in Inventories of $1.02 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInInventories · last filed 2026-08-06
- X4 PHARMACEUTICALS, INC increase (decrease) in inventories for the quarter ending 2026-06-30 was $865.00K, a 967.90% increase year-over-year.
- X4 PHARMACEUTICALS, INC increase (decrease) in inventories for the quarter ending 2026-03-31 was $158.00K, a 41.91% decline year-over-year.
- X4 PHARMACEUTICALS, INC increase (decrease) in inventories for the quarter ending 2025-12-31 was $399.00K, a 7.26% increase year-over-year.
- X4 PHARMACEUTICALS, INC increase (decrease) in inventories for the quarter ending 2025-09-30 was $910.00K, a 43.62% decline year-over-year.
- X4 PHARMACEUTICALS, INC increase (decrease) in inventories for fiscal 2025 was $1.66M, a 41.00% decline from fiscal 2024.
- X4 PHARMACEUTICALS, INC increase (decrease) in inventories for fiscal 2024 was $2.82M.
- X4 PHARMACEUTICALS, INC increase (decrease) in inventories for fiscal 2023 was $0.00.
- X4 PHARMACEUTICALS, INC increase (decrease) in inventories for fiscal 2022 was $0.00.
| Period end | Increase (Decrease) in Inventories 3 month | Increase (Decrease) in Inventories 6 month | Increase (Decrease) in Inventories 9 month | Increase (Decrease) in Inventories 12 month |
|---|---|---|---|---|
| 2026-06-30 | $865.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $1.02M 10-Q · filed 2026-08-06 | $1.42M derived: sum of 3 quarters · filed 2026-08-06 | $2.33M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $158.00K 10-Q · filed 2026-05-06 | $557.00K derived: sum of 2 quarters · filed 2026-05-06 | $1.47M derived: sum of 3 quarters · filed 2026-05-06 | $1.55M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $399.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $1.31M derived: sum of 2 quarters · filed 2026-03-17 | $1.39M derived: sum of 3 quarters · filed 2026-08-06 | $1.66M 10-K · filed 2026-03-17 |
| 2025-09-30 | $910.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $991.00K derived: sum of 2 quarters · filed 2026-08-06 | $1.26M 10-Q · filed 2025-11-05 | $1.64M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $81.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $353.00K 10-Q · filed 2026-08-06 | $725.00K derived: sum of 3 quarters · filed 2026-08-06 | $2.34M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $272.00K 10-Q · filed 2026-05-06 | $644.00K derived: sum of 2 quarters · filed 2026-05-06 | $2.26M derived: sum of 3 quarters · filed 2026-05-06 | $3.09M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $372.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $1.99M derived: sum of 2 quarters · filed 2026-03-17 | $2.82M derived: sum of 3 quarters · filed 2026-03-17 | $2.82M 10-K · filed 2026-03-17 |
| 2024-09-30 | $1.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $2.44M derived: sum of 2 quarters · filed 2025-11-05 | $2.44M 10-Q · filed 2025-11-05 | $2.44M derived: sum of 4 quarters · filed 2026-03-17 |
| 2024-06-30 | $831.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-08 | $831.00K 10-Q · filed 2025-08-08 | $831.00K derived: sum of 3 quarters · filed 2026-03-17 | $831.00K derived: sum of 4 quarters · filed 2026-03-17 |
| 2024-03-31 | $0.00 10-Q · filed 2025-05-01 | $0.00 derived: sum of 2 quarters · filed 2026-03-17 | $0.00 derived: sum of 3 quarters · filed 2026-03-17 | |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $0.00 derived: sum of 2 quarters · filed 2026-03-17 | $0.00 10-K · filed 2026-03-17 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $0.00 10-Q · filed 2024-11-13 | ||
| 2023-06-30 | $0.00 10-Q · filed 2024-08-08 | |||
| 2022-12-31 | $0.00 10-K · filed 2025-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |